Cas no 50-56-6 (Oxytocin)
Oxytocin Chemical and Physical Properties
Names and Identifiers
-
- oxytocin
- oxytocin lyophilized
- oxytocin acetate
- H-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 Disulfide bond
- H-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (Disulfide bond)
- oxtocin
- (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-13-[(2s)-butan-2-yl]-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(1s)-1-(carbamoylmethylcarbamoyl)-3-methyl-butyl]pyrrolidine-2-carboxamide
- Oxytocin Solution
- Oxytocin acetate salt hydrate
- Oxytocin（2mg）
- α-Hypophamine Oxytocic hormone
- Oxytocic hormone
- Pitocin
- α-Hypophamine
- (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-13-[(2S)-butan-2-yl]-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4
- Ocytocin
- Endopituitrina
- Orasthin
- Syntocinon
- Oxytocine
- Oxitocina
- Oxytocinum
- (1-Hemicystine)oxytocin
- Piton S
- 3-Isoleucine-8-leucine vasopressin
- Partocon
- Oxystin
- alpha-Hypophamine
- Synthetic oxytocin
- 1JQS135EYN
- Ocytocinum
- Syntocinone
- Uteracon
- Syntocin
- Synpitan
- Utedrin
- Presoxin
- Di-sipidin
- Nobitocin S
- Atonin O
- Oxetakain [Czech]
- Ossitocina [DCIT]
- Oxytocinum [INN-Latin]
- Oxytocine [INN-
- [3H]OT (human, mouse, rat)
- OXYTOCIN (USP IMPURITY)
- SR-01000945111-1
- OXYTOCIN 20 USP UNITS IN DEXTROSE 5%
- Intertocine S
- Oxitocina [INN-Spanish]
- Oxoject
- OXYTOCIN 10 USP UNITS IN DEXTROSE 5%
- (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
- D00089
- HSDB 2182
- 1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide
- CHEMBL395429
- BCBcMAP01_000094
- (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
- CHEBI:7872
- [3H]oxytocin
- Vasopressin, 3-L-isoleucine-8-L-leucine-
- A828179
- OXYTOCIN (MART.)
- Oxytocin [USP:INN:BAN:JAN]
- GTPL2176
- Oxytocin, European Pharmacopoeia (EP) Reference Standard
- Oxetakain
- AKOS015994657
- Oxytocin, lyophilized powder, ~15 IU/mg solid (Prepared from synthetic oxytocin)
- OXYTOCIN (USP MONOGRAPH)
- Oxytocin-(leucine-5,5,5-d3, glycine-2,2-d2) trifluoroacetate salt
- D0T6FH
- CYIQNCPLG
- W-105951
- Oxytocin (Syntocinon)
- 1-[19-amino-7-(2-amino-2-oxo-ethyl)-10-(3-amino-3-oxo-propyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-sec-butyl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[1-[(2-amino-1-methyl-2-oxo-ethyl)carbamoyl]-3-methyl-butyl]pyrrolidine
- D0M3FJ
- SCHEMBL29048
- H01BB02
- Oxytocin [USAN:BAN:INN:JAN]
- TNX-1900
- C43H66N12O12S2
- Oxytocin-
- Recombinant Oxytocin
- OXYTOCIN 5 USP UNITS IN DEXTROSE 5%
- SR-01000945111
- HB2929
- Oxytocin (intranasal/ muco system, autism)
- TI-001
- Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, cyclic 1-6 disulfide
- AC-28730
- 1-(((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-((1S)-1-methylpropyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl)carbonyl)-L-prolyl-L-leucylglycinamide
- XNOPRXBHLZRZKH-DSZYJQQASA-N
- perlacton
- 50-56-6
- HS-2021
- (Gly-9 = C-terminal amide, disulfide bridge between 1 - 6)
- BRN 3586108
- TNX1900
- DTXCID4028335
- TTA-121
- L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide
- AMY25364
- UNII-1JQS135EYN
- oxytocin, for bioassay
- Oxytocine [INN-French]
- OXYTOCIN (USP-RS)
- OXT
- Oxytocin,(S)
- Oxytocin (TN)
- a-Hypophamine
- MFCD00076731
- NCGC00167132-01
- EINECS 200-048-4
- GTPL2174
- Glycinamide, L-cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-propyl-L-leucyl-, cyclic (1-6)-di-
- Otx
- DTXSID8048361
- C00746
- Q169960
- GLYCINAMIDE, L-CYSTEINYL-L-TYROSYL-L-ISOLEUCYL-L-GLUTAMINYL-L-ASPARAGINYL-L-CYSTEINYL-L-PROLYL-L-LEUCYL-, CYCLIC (1->6)-DISULFIDE
- Oxytocin (JP17/USP/INN)
- Piton-S
- (1-Hemicystine)-oxytocin
- L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic (1-->6)-disulfide
- C43-H66-N12-O12-S2
- Syntocinon (TN)
- Pitocin (TN)
- Ossitocina
- Oxytocin, United States Pharmacopeia (USP) Reference Standard
- L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic (1-6)-disulfide
- BDBM50205990
- OT
- Oxytocinum (INN-Latin)
- Oxytocin (USP:INN:BAN:JAN)
- Oxitocina (INN-Spanish)
- Oxytocin (Label Under Distributors)
- PVL Oxytocin Injectable
- Oxytocine (INN-French)
- Oxytocin (High Potency Powder)
- Oxytocin Injectable
- HY-17571
- BRD-K25243230-001-01-2
- Oxytocin (JP18/USP/INN)
- SBI-0654087.0001
- FO35402
- 200-048-4
- Oxytocin
-
- MDL： MFCD00076731
- Inchi： 1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1
- InChI Key： XNOPRXBHLZRZKH-DSZYJQQASA-N
- SMILES： S1C[C@@H](C(N2CCC[C@H]2C(N[C@H](C(NCC(N)=O)=O)CC(C)C)=O)=O)NC([C@H](CC(N)=O)NC([C@H](CCC(N)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC2C=CC(=CC=2)O)NC([C@H](CS1)N)=O)=O)=O)=O)=O
- BRN： 3586108
Computed Properties
- Exact Mass: 1006.44000
- Monoisotopic Mass: 1006.436457
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 12
- Hydrogen Bond Acceptor Count: 15
- Heavy Atom Count: 69
- Rotatable Bond Count: 17
- Complexity: 1870
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 9
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: 1001
- XLogP3: -2.6
- Topological Polar Surface Area: 450
Experimental Properties
- Color/Form: Lyophilized powder
- Density: 1.27 g/cm3
- Melting Point: 192-194°C
- Boiling Point: 1533.3°C at760mmHg
- Flash Point: 881.1°C
- Refractive Index: 1.554
- Water Partition Coefficient: Soluble in water.
- PSA: 450.13000
- LogP: 1.55630
- Solubility: Soluble in water, acetone, butanol and dilute acetic acid, insoluble in ether and petroleum ether
- Vapor Pressure: 0mmHg at 25°C
- Merck: 13,7049
- Fluka: 3-8-10-23
- Specific Rotation: D22 -26.2° (c = 0.53)
Oxytocin Security Information
- Signal Word：Warning
- Hazard Statement： H315; H319; H335
- Warning Statement： P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501
- Hazardous Material transportation number：3249
- WGK Germany：3
- Hazard Category Code： R36/37/38: irritating to eyes, respiratory tract and skin
- Safety Instruction： S26; S36
- FLUKA BRAND F CODES：3-8-10-23
- RTECS：RS7534000
-
Hazardous Material Identification：
- Packing Group：II
- Hazard Level：6.1(a)
- Safety Term：6.1(a)
- Packing Group：II
- Risk Phrases：R36/37/38
- Storage Condition：2-8°C
- HazardClass：6.1
- PackingGroup：II
Oxytocin Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Fluorochem | M02852-1g |
Oxytocin |
50-56-6 | 98+% | 1g |
￡220.00 | 2021-07-01 | |
| Fluorochem | M02852-5g |
Oxytocin |
50-56-6 | 98+% | 5g |
￡957.00 | 2021-07-01 | |
| HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI | SX7662-100mg |
Oxytocin |
50-56-6 | ≥98% | 100mg |
￥1800元 | 2023-09-15 | |
| HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI | SX7662-25mg |
Oxytocin |
50-56-6 | ≥98% | 25mg |
￥590元 | 2023-09-15 | |
| Chemenu | CM100719-10mg |
Oxytocin |
50-56-6 | 98% | 10mg |
$108 | 2021-06-09 | |
| ChemScence | CS-3115-2mg |
Oxytocin |
50-56-6 | 99.79% | 2mg |
$65.0 | 2022-04-27 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-GV554-5mg |
Oxytocin |
50-56-6 | 98% (contains 6-10%HOAc) | 5mg |
757CNY | 2021-05-08 | |
| FUJIFILM | 335-40841-0.5mg |
Oxytocin |
50-56-6 | 0.5mg |
JPY 5000 | 2023-09-15 | ||
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | O878760-5mg |
Oxytocin |
50-56-6 | ≥98% | 5mg |
￥520.00 | 2022-01-13 | |
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | O878760-10mg |
Oxytocin |
50-56-6 | ≥98% | 10mg |
￥978.00 | 2022-01-13 |
Oxytocin Suppliers
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Oxytocin Related Literature
-
J. H. Gaddum,H. O. Schild,G. F. Somers,G. A. Stewart Analyst 1950 75 530
-
Kohei Ohshiro,Yui Sasaki,Qi Zhou,Xiaojun Lyu,Yusuke Yamanashi,Katsumasa Nakahara,Hirokazu Nagaoka,Tsuyoshi Minami Analyst 2022 147 1055
-
Justin J. O’Sullivan,Kylie S. Uyeda,Michael J. Stevenson,Marie C. Heffern RSC Chem. Biol. 2023 4 165
-
Stephen A. Cochrane,Zedu Huang,John C. Vederas Org. Biomol. Chem. 2013 11 630
-
Michael J. Stevenson,Kylie S. Uyeda,Nathaniel H. O. Harder,Marie C. Heffern Metallomics 2019 11 85
Additional information on Oxytocin
Introduction to Oxytocin (CAS No: 50-56-6) and Its Recent Research Developments
Oxytocin, a peptide hormone with the chemical formula C51H72O12N2, is a compound that has garnered significant attention in the field of biomedical research due to its profound effects on social behavior, physiology, and psychology. The chemical structure of Oxytocin (CAS No: 50-56-6) consists of nine amino acids arranged in a specific sequence, which contributes to its unique biological activity. This hormone is primarily known for its role in facilitating childbirth and lactation, but recent studies have unveiled a broader spectrum of functions that make it a subject of intense scientific inquiry.
The primary biological function of Oxytocin is to induce uterine contractions during labor and to promote milk ejection during breastfeeding. These processes are critical for maternal health and neonatal development. However, the hormone's influence extends beyond these well-documented roles. Recent research has highlighted its involvement in social bonding, trust, and empathy, suggesting that it may play a pivotal role in human social interactions. The discovery of these social functions has led to Oxytocin being dubbed the "love hormone" or "bonding hormone," reflecting its significance in both physiological and psychological contexts.
In terms of pharmacological applications, Oxytocin has been widely used in medical settings for its ability to control bleeding after childbirth and to enhance uterine contractions in cases of insufficient labor. The synthetic form of this hormone, available under various brand names, is a crucial component in obstetric care. Additionally, research into the therapeutic potential of Oxytocin has expanded to include treatments for various medical conditions, such as anxiety disorders, depression, and even autism spectrum disorders. The growing body of evidence supporting its therapeutic efficacy has spurred further investigation into its mechanisms of action.
The latest advancements in the study of Oxytocin have focused on understanding how it interacts with the brain's reward system and how it modulates neural pathways associated with social behavior. Studies using neuroimaging techniques have revealed that administration of Oxytocin can alter activity in brain regions such as the prefrontal cortex and the amygdala, which are involved in decision-making, emotional processing, and social cognition. These findings have significant implications for developing new therapeutic strategies targeting mental health conditions.
The development of novel delivery systems for Oxytocin is another area of active research. Traditional methods of administering this hormone involve intravenous injections or nasal sprays, which can be cumbersome for patients. To address this limitation, researchers are exploring alternative delivery methods such as transdermal patches and microencapsulation techniques. These innovations aim to improve patient compliance and enhance the bioavailability of Oxytocin, thereby optimizing its therapeutic effects.
In conclusion, the multifaceted roles of Oxytocin (CAS No: 50-56-6) make it a fascinating subject of biomedical research. From its well-established functions in childbirth and lactation to its emerging roles in social behavior and mental health treatment, this hormone continues to captivate scientists worldwide. The ongoing exploration into its mechanisms of action and therapeutic potential holds promise for developing innovative treatments that could significantly improve human health outcomes.
50-56-6 (Oxytocin) Related Products
- 107761-42-2(β-Amyloid (1-42), human TFA)
- 128270-60-0(Bivalirudin)
- 50-57-7(Lysipressin)
- 60-32-2(6-Aminocaproic acid)
- 9034-50-8(Vasotocin)
- 598-41-4(2-Aminoacetamide)
- 26995-91-5(Oxytocin,4-L-threonine- (8CI,9CI))
- 9032-75-1(Pectinase)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
